Checkpoint Inhibitors Show Promise in Triple-Negative Breast Cancer
Read More >>
View Free CME from PER >>
Adjuvant Trastuzumab Benefit Elucidated in Small HER2-Positive Breast Cancer
Medivation Acquires BioMarin's PARP Inhibitor Talazoparib
HER2-Positive Breast Cancer Treatment Options Growing
PIK3CA Confers Resistance to Trastuzumab/Lapatinib Combo in HER2-Positive Breast Cancer
Molecular Imaging May Help Tailor Breast Cancer Therapies
View More >>
- A Network of Your Peers
View more >>
Dr. Kass on Optimal Treatment Sequencing in HER2-Positive Breast Cancer
Dr. O'Shaughnessy Discusses New Developments in Molecular Profiling in Breast Cancer
Overcoming Endocrine Resistance in Breast Cancer
Dr. O'Shaughnessy on Using Phosphoprotein Assays to Personalize Treatment for Breast Cancer
Future Approaches in Breast Cancer
Carlos L. Arteaga, MD; Edith Perez, MD; Debu Tripathy, MD; Joyce O’Shaughnessy, MD, and Denise A. Yardley, MD, share their concluding thoughts regarding the future of breast cancer diagnosis and treatment.
TNT Study for Triple-Negative or BRCA1/2 Breast Cancer
In this segment, Debu Tripathy, MD; Joyce O’Shaughnessy, MD, and Edith Perez, MD, examine results from the TNT clinical trial, which evaluated the use of docetaxel or carboplatin in individuals with triple negative breast cancer.
Practical Considerations in Breast Cancer
Moderated by Adam M. Brufsky, MD, PhD, this panel discussion includes expert perspectives from Kimberly L. Blackwell, MD, Joyce A. O'Shaughnessy, MD, Mark Pegram, MD, Hope S. Rugo, MD, and Denise A. Yardley, MD.
Most Popular Right Now
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
666 Plainsboro Road
Plainsboro, NJ 08536
Copyright OncLive 2006-2015
Intellisphere, LLC. All Rights Reserved.